Roivant Subsidiaries Secure $2.25B Moderna Settlement; Company Greenlights $1B Buyback
Roivant’s subsidiaries Genevant Sciences and Arbutus Biopharma secured a $2.25 billion global settlement with Moderna, receiving $950 million upfront in July 2026 and $1.3 billion contingent on a favorable appellate ruling. Roivant’s board approved a $1 billion share repurchase program, including the $500 million authorization from June 2025.
1. Settlement Details
Genevant Sciences and Arbutus Biopharma secured a $2.25 billion global settlement with Moderna, including a $950 million upfront payment in July 2026 and $1.3 billion contingent upon an appellate ruling that Section 1498 does not bar infringement claims.
2. License Grants and Patent Judgment
The agreement grants Moderna a global non-exclusive license to use LNP delivery technology in SM-102-containing mRNA vaccines for infectious disease and includes entry of judgment of infringement and no invalidity on four asserted patents.
3. Share Repurchase Authorization
Roivant’s board authorized a $1 billion share repurchase program, incorporating the $500 million share buyback approved in June 2025, to deploy settlement proceeds and strengthen capital return to shareholders.
4. Litigation Status and Outlook
Roivant will continue its ongoing litigation against Pfizer/BioNTech following a favorable Markman ruling and will host an investor call on March 3, 2026 to discuss the settlement’s impact and financial outlook.